Fair enough. A company that has surprised on the upside so many times, and so outlandishly, is bound to disappoint sooner or later. But is this really where Apple belongs trading – alongside, based on its PE ratio, such no-growth companies as pharmaceutical makers Eli Lilly (LLY), Sanofi (SNY) and GlaxoSmithKline (GSK)?